Peptide fragments of bradykinin show unexpected biological activity not mediated by B1 or B2 receptors. (9th February 2022)
- Record Type:
- Journal Article
- Title:
- Peptide fragments of bradykinin show unexpected biological activity not mediated by B1 or B2 receptors. (9th February 2022)
- Main Title:
- Peptide fragments of bradykinin show unexpected biological activity not mediated by B1 or B2 receptors
- Authors:
- Souza‐Silva, Igor Maciel
de Paula, Cristiane Amorim
Bolais‐Ramos, Lucas
Santos, Anderson Kenedy
da Silva, Filipe Alex
de Oliveira, Vívian Louise Soares
da Rocha, Isabella Domingos
Antunes, Maísa Mota
Cordeiro, Lídia Pereira Barbosa
Teixeira, Vanessa Pereira
Scalzo Júnior, Sérgio Ricardo Aluotto
Raabe, Adriana Campezatto
Guimaraes, Pedro Pires Goulart
Amaral, Flávio Almeida
Resende, Jarbas Magalhães
Fontes, Marco Antônio Peliky
Menezes, Gustavo Batista
Guatimosim, Silvia
Santos, Robson Augusto Souza
Verano‐Braga, Thiago - Other Names:
- Stefanska Barbara guestEditor.
Tucker Steven guestEditor.
MacEwan David guestEditor. - Abstract:
- Abstract : Background and Purpose: Bradykinin (BK‐(1–9)) is an endogenous nonapeptide involved in multiple physiological and pathological processes. Peptide fragments of bradykinin are believed to be biologically inactive. We have now tested the two major peptide fragments of bradykinin in human and animals. Experimental Approach: BK peptides were quantified by MS in male rats. NO release was quantified from human, mouse and rat cells loaded with DAF‐FM. Rat aortic rings were used to measure vascular reactivity. Changes in BP and HR were measured in conscious male rats. To evaluate pro‐inflammatory effects both vascular permeability and nociception were measured in adult mice. Key Results: BK‐(1–7) and BK‐(1–5) are produced in vivo from BK‐(1–9). Both peptides induced NO production in all cell types tested. However, unlike BK‐(1–9), NO production elicited by BK‐(1–7) or BK‐(1–5) was not inhibited by B1 or B2 receptor antagonists. BK‐(1–7) and BK‐(1–5) induced concentration‐dependent vasorelaxation of aortic rings, without involvement of B1 or B2 receptors. Intravenous or intra‐arterial administration of BK‐(1–7) or BK‐(1–5) induced similar hypotensive response in vivo . Nociceptive responses of BK‐(1–7) and BK‐(1–5) were reduced compared to BK‐(1–9), and no increase in vascular permeability was observed for BK‐(1–9) fragments. Conclusions and Implications: BK‐(1–7) and BK‐(1–5) are endogenous peptides present in plasma. BK‐related peptide fragments show biological activity,Abstract : Background and Purpose: Bradykinin (BK‐(1–9)) is an endogenous nonapeptide involved in multiple physiological and pathological processes. Peptide fragments of bradykinin are believed to be biologically inactive. We have now tested the two major peptide fragments of bradykinin in human and animals. Experimental Approach: BK peptides were quantified by MS in male rats. NO release was quantified from human, mouse and rat cells loaded with DAF‐FM. Rat aortic rings were used to measure vascular reactivity. Changes in BP and HR were measured in conscious male rats. To evaluate pro‐inflammatory effects both vascular permeability and nociception were measured in adult mice. Key Results: BK‐(1–7) and BK‐(1–5) are produced in vivo from BK‐(1–9). Both peptides induced NO production in all cell types tested. However, unlike BK‐(1–9), NO production elicited by BK‐(1–7) or BK‐(1–5) was not inhibited by B1 or B2 receptor antagonists. BK‐(1–7) and BK‐(1–5) induced concentration‐dependent vasorelaxation of aortic rings, without involvement of B1 or B2 receptors. Intravenous or intra‐arterial administration of BK‐(1–7) or BK‐(1–5) induced similar hypotensive response in vivo . Nociceptive responses of BK‐(1–7) and BK‐(1–5) were reduced compared to BK‐(1–9), and no increase in vascular permeability was observed for BK‐(1–9) fragments. Conclusions and Implications: BK‐(1–7) and BK‐(1–5) are endogenous peptides present in plasma. BK‐related peptide fragments show biological activity, not mediated by B1 or B2 receptors. These BK fragments could constitute new, active components of the kallikrein–kinin system. … (more)
- Is Part Of:
- British journal of pharmacology. Volume 179:Number 12(2022)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 179:Number 12(2022)
- Issue Display:
- Volume 179, Issue 12 (2022)
- Year:
- 2022
- Volume:
- 179
- Issue:
- 12
- Issue Sort Value:
- 2022-0179-0012-0000
- Page Start:
- 3061
- Page End:
- 3077
- Publication Date:
- 2022-02-09
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.15790 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21525.xml